首页> 外文期刊>Cancer biology & therapy >Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa
【24h】

Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa

机译:VEGFR抑制剂索拉非尼与mTOR抑制剂西罗莫司的联合靶向治疗可引起快速进行性子宫PEComa的显着反应

获取原文
获取原文并翻译 | 示例
           

摘要

Perivascular epithelioid cell tumor is a rare tumor. To date, there is no consensus of therapy to be recommended for unresectable disease. For a low incidence and a rarely curable disease, the finding of new therapy is essential.Here we report the first case of a patient with perivascular epithelioid cell tumor whose disease had a rapid progression after surgery and had a rapid remarkable response of combination therapy of a VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus.This result may have potential to deliver a new treatment option and inhibiting the mTOR pathway combined with inhibiting the VEGF pathways may be a useful strategy for malignant PEComas.
机译:血管周上皮样细胞瘤是一种罕见的肿瘤。迄今为止,对于无法切除的疾病,尚无推荐治疗的共识。对于低发病率和难于治愈的疾病,必须找到新的治疗方法。在此,我们报道了第一例血管周上皮样细胞瘤患者,该患者术后病情迅速发展,并且联合用药的反应迅速显着。 VEGFR抑制剂索拉非尼与mTOR抑制剂西罗莫司(sirolimus)联用。这一结果可能具有提供新的治疗选择的潜力,抑制mTOR途径与抑制VEGF途径结合可能是恶性PEComas的有用策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号